Oral Hypoglycemic Agents Market Report 2026

The oral hypoglycemic agents market size has grown steadily in recent years. It will grow from $59.57 billion in 2025 to $62.48 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising global diabetes prevalence, widespread use of metformin, expansion of generic drug availability, increased diabetes screening, growth of hospital pharmacy distribution.

The oral hypoglycemic agents market size is expected to see steady growth in the next few years. It will grow to $75.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing lifestyle-related diabetes cases, rising demand in emerging economies, advancements in oral drug formulations, expansion of preventive diabetes care, growth of long-term diabetes management programs. Major trends in the forecast period include increasing adoption of combination oral therapies, growing use of metformin-based regimens, rising focus on early type 2 diabetes management, expansion of extended-release oral formulations, increasing demand for cost-effective diabetes drugs.

The increasing prevalence of type 2 diabetes is expected to drive the growth of the oral hypoglycemic agents market in the coming years. Type 2 diabetes is a chronic metabolic disorder in which the body does not use insulin effectively, resulting in elevated blood glucose levels. Its prevalence is rising due to sedentary lifestyles, which reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents help manage type 2 diabetes by lowering blood glucose levels through mechanisms such as improving insulin sensitivity, stimulating insulin secretion, or reducing glucose absorption. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, reported that nearly 589 million adults aged 20-79 were living with diabetes worldwide, with this number projected to rise to 853 million by 2050. Consequently, the growing incidence of type 2 diabetes is fueling the oral hypoglycemic agents market.

Leading companies in the oral hypoglycemic agents market are focusing on developing innovative products, such as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), to enhance glycemic control and reduce diabetes-related complications. SGLT2 inhibitors are a class of oral medications that lower blood glucose by preventing the kidneys from reabsorbing glucose, causing excess glucose to be excreted in the urine. This mechanism helps improve glycemic control, reduce body weight, and lower the risk of heart and kidney complications in patients with type 2 diabetes. For example, in June 2024, AstraZeneca plc, a UK-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin), an oral SGLT2 inhibitor designed for the treatment of pediatric type 2 diabetes in patients aged 10 years and older. The approval includes once-daily oral dosing, demonstrated safety and efficacy in pediatric clinical trials, and a first-in-class mechanism of action. Farxiga enhances treatment accessibility, supports better long-term glycemic control, and expands therapeutic options within the oral hypoglycemic agents market.

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to enhance its presence in the obesity and diabetes treatment market by expanding its pipeline of advanced incretin-based therapies. Carmot Therapeutics Inc. is a U.S.-based company focused on developing incretin-based therapies for obesity, diabetes, and related metabolic disorders.

Major companies operating in the oral hypoglycemic agents market are Merck Sharp & Dohme Corp., AstraZeneca plc, Boehringer Ingelheim Ltd., Takeda Pharmaceuticals Limited, Bayer AG, Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Huadong Medicine Co. Ltd., Wanbang Biopharmaceuticals Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Biocon Limited.

North America was the largest region in the oral hypoglycemic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral hypoglycemic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oral hypoglycemic agents market by increasing the cost of imported APIs and pharmaceutical intermediates used in diabetes drug manufacturing. These impacts are most pronounced in generic drug manufacturing hubs across Asia Pacific and Europe, where large scale production depends on cross border sourcing. Rising tariff related expenses have placed pressure on drug pricing and manufacturing margins. This has influenced procurement planning and competitive dynamics in both domestic and export markets. However, tariffs have encouraged domestic API production, localized sourcing strategies, and improved long term supply chain resilience.

The oral hypoglycemic agents market research report is one of a series of new reports that provides oral hypoglycemic agents market statistics, including oral hypoglycemic agents industry global market size, regional shares, competitors with a oral hypoglycemic agents market share, detailed oral hypoglycemic agents market segments, market trends and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. This oral hypoglycemic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral hypoglycemic agents (OHAs) are medications taken orally to help lower blood glucose levels in individuals with type 2 diabetes mellitus. These drugs work through various mechanisms, including stimulating insulin secretion, enhancing insulin sensitivity, reducing glucose absorption in the gut, or decreasing glucose production by the liver. OHAs are typically prescribed when lifestyle modifications, such as diet and exercise, are insufficient to maintain blood sugar control.

The main types of oral hypoglycemic agents include sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas are a class of OHAs that stimulate the pancreas to release insulin by acting on beta cells, helping to lower blood glucose levels in type 2 diabetes patients. These agents are available in oral tablets, oral liquids, extended-release formulations, and combination therapy forms. They are used in patients with type 2 diabetes, pre-diabetes, obesity or overweight, and those with multiple comorbidities. OHAs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes or long-term care facilities, with end-users including hospitals and clinics.

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.